44 results about "C57BL/6" patented technology

The invention discloses an application of bulbus lilii glycoside B. The application is that bulbus lilii glycoside B is used as a unique active component or one of the active components to prepare a product for preventing or / and treating skin photoaging diseases. Experimental results of the invention show that lilium brownii glycoside B can significantly improve the cell viability of UVA-induced human skin fibroblasts, can reduce the number of beta-galactosidase positive cells in the UVA-induced human skin fibroblasts and reduce lipofuscin deposition, and can significantly improve the photoaging of the UVA-induced skin fibroblasts. Meanwhile, the skin photoaging grading of the back of a C57BL / 6 mouse induced by UVA can be remarkably improved. Therefore, the bulbus lilii glycoside B is expected to be used as an active ingredient for preparing medicines or cosmetics for preventing or / and treating the skin photoaging diseases, and particularly has important significance and remarkable application value for preventing or / and treating the UVA-induced skin photoaging diseases.

The present application provides a mouse model for studying microsatellite stable and unstable intestinal cancer. Specifically, the present application provides the use of a hybrid mouse in a reagent or kit for preparing a mouse model animal for constructing MSS type intestinal cancer and MSI-H type intestinal cancer, wherein the mouse is a F1 generation of C57BL / 6 x BALB / c. The mouse model of the present application provides the same genetic background for MSS type intestinal cancer cells and MSI-H type intestinal cancer cells, making the research of MSS type intestinal cancer and MSI-H type intestinal cancer more scientific.

This invention provides a method for constructing a fluorescently traced mouse model and its application in the sorting of Mcpt4-positive and negative mast cells. First, the Cre gene is knocked into the Mcpt4 gene sequence of C57BL / 6 mice using CRISPR / Cas9 technology. Then, through animal hybridization and Cre-loxP recombination technology, a fluorescently traced mouse model of Mcpt4-positive mast cells is obtained. The fluorescently traced mouse model possesses a dual-fluorescent reporter gene system consisting of the red fluorescent protein tdTomato and the green fluorescent protein ZsGreen. Mcpt4-positive mast cells exhibit red fluorescence, while other Mcpt4-negative cells exhibit green fluorescence. Using this fluorescently traced mouse model, Mcpt4-positive and negative mast cells can be rapidly, accurately, and effectively sorted, providing a reliable technical basis for exploring the roles and mechanisms of Mcpt4-positive and negative mast cells in immune responses.

The application belongs to the technical field of biotechnology, and particularly relates to a colorectal cancer high liver metastasis cell line and a preparation method and application thereof. The cell line was preserved in the China Center for Type Culture Collection on January 14, 2026, and the preservation number is CCTCC NO: C202618. The cell line is derived from a mouse colorectal cancer cell line MC38, and is constructed by lentivirus transfection to express luciferase stably, and is obtained by continuously performing at least five rounds of liver metastasis tumor orthotopic iteration screening in C57BL / 6 mice through rectal submucosal injection. The MC38-P06 cell line provided by the application has a significantly enhanced liver metastasis ability, a shorter MC38-P01 model time, a higher liver tumor load, and a shorter mouse survival period, and can be used for screening and evaluating anti-liver metastasis drugs, researching liver microenvironment regulation mechanisms, and identifying liver metastasis related diagnostic markers.

The invention relates to an application of an aureomycin A derivative in preparation of an anti-tumor drug, the anti-tumor drug is a drug for preventing or treating liver cancer, and the aureomycin A derivative is selected from a compound shown as a formula (I), or a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a pharmaceutically acceptable ester or a pharmaceutically acceptable solvate of the compound. The aureomycin A derivative disclosed by the invention can be used for remarkably inhibiting the proliferation of liver cancer cells Hepa1-6, and the half inhibitory concentration (IC50 value) is 0.4821 mu g / mL and 0.1701 mu g / mL respectively; 11 days after administration, the tumor volume of a Hepa1-6 ectopic transplantation C57BL / 6 mouse is reduced, and the tumor weight of a Hepa1-6 tumor ectopic transplantation tumor is reduced; the aureomycin A derivative has the effects of remarkably inhibiting proliferation of liver cancer cells at the cellular level and remarkably reducing tumor growth of the liver cancer cells at the animal level, and a research direction is provided for development of new drugs.

The invention relates to application of lactobacillus muricatum in preparation of a medicine for treating oral cancer, the oral cancer is oral squamous cell carcinoma, a C57BL / 6 mouse tongue squamous cell carcinoma model induced by a 4-NQO water drinking method and a C3H / HeN subcutaneous tumor model inoculated by SCC7 tumor cells are constructed, and the lactobacillus muricatum has a remarkable inhibition effect on the oral cancer; experiments prove that the number / area / volume / weight of tumors is remarkably reduced by the lactobacillus muricatum, tumor marginal infiltration and abnormal karyokinesis are effectively inhibited, the expression quantity of tumor proliferation markers is remarkably reduced, and obvious pathological changes do not appear in main organs (heart, liver, spleen, lung and kidney) of mice. The method for minimally invasive injection of the lactobacillus muricatum into the oral squamous cell cancer tumor is safe, drug resistance is not easily induced, the treatment scheme is standardized, and the method has good clinical application potential.

This invention belongs to the field of tumor biology and drug screening technology, specifically disclosing a human EGFR mutation-driven mouse primary lung cancer cell line, its construction method, and its applications. The cell line, ZST-1, is a human EGFR (L858R / T790M) mutation-driven lung cancer cell line derived from mouse primary lung cancer. It is stable, capable of subcutaneous tumor formation in C57BL / 6 mice, and simultaneously expresses Luciferase and tdTomato reporter genes. Its construction method includes obtaining transgenic mice, virus-induced tumor formation, continuous in vivo passage in nude mice, and in vitro culture and screening steps. This cell line can be applied to in vitro screening and efficacy evaluation of human EGFR mutation-targeting drugs, research on EGFR-TKI resistance mechanisms, tumor bioluminescence imaging and fluorescence tracing, and in vivo tumorigenesis and efficacy experiments in an immune-intact C57BL / 6 background.

The invention discloses a high-efficiency C57BL / 6 mouse in-vitro fertilization method, relates to use of an in-vitro fertilization method in the technical field of biology, and particularly relates to a method for obtaining more high-quality fertilized eggs for gene editing in an in-vitro fertilization process of small animal gene editing model construction. Therefore, the animal cost of gene editing is greatly reduced, and wide application is promoted.

The invention relates to the technical field of bioengineering, and particularly discloses a construction method and application of a mixed type liver cancer mouse model, pCMV-Cre, pT3-EF1 alphaH-c-Met, pT3-EF1 alphaH-N90-beta-catenin plasmids and pCMV (CAT) T7-SB100 transposase are mixed to prepare an injection, and the injection is injected into a C57BL / 6-MFN1flox / flox mouse at the age of 6 weeks in a caudal vein mode to obtain the mixed type liver cancer mouse model. The construction method of the mixed type liver cancer mouse model is stable, reliable, efficient and easy to implement, and the constructed mixed type liver cancer mouse model can be used for exploring the generation and development mechanism of the mixed type liver cancer and researching treatment targets and can also be used for screening drugs for treating the mixed type liver cancer.

The invention discloses a CAR-T cell for overexpressing H2A. Z as well as a preparation method and application of the CAR-T cell. In particular, the present invention provides a chimeric antigen receptor comprising an H2A. Z gene or a variant having the same function as the H2A. Z gene. The chimeric antigen receptor further comprises a signal peptide, a CLDN18.2-targeted antigen binding structural domain, a hinge region, a transmembrane region, a co-stimulation structural domain and an intracellular signal transduction structural domain. In a C57BL / 6 mouse model inoculated with CLDN18.2 positive tumor cells MC38-CLDN18.2 and KPC, the treatment effect of the CLDN18.2-CAR-T cell for overexpressing the H2AZ.1 gene disclosed by the invention is obviously superior to that of a CLDN18.2-CAR-T control group without overexpressing the H2AZ.1 gene.

The present application relates to the technical field of medicine, especially relates to application of a small molecule compound LZ-09 in preparation of a medicine for treating and / or preventing multiple sclerosis. The present application adopts H2O2 damage OLN-93 cells as a nerve cell oxidative stress model, and the result shows that LZ-09 treatment significantly weakens the cell viability decrease caused by H2O2. The classic EAE model is made by using MOG35-55 to induce C57BL / 6 mice, and it is found that after LZ-09 intervention, the mouse neurological deficit symptom score is significantly reduced, and the disease progression is delayed, and spinal cord tissue HE and LFB staining find that the inflammation infiltration and demyelination are reduced. Therefore, the compound can effectively alleviate the symptoms of multiple sclerosis, can be used as a medicine for treating multiple sclerosis, and has wide development and application prospect.

The invention relates to the field of biological medicines, in particular to a preparation method of a novel black soybean hull extract and application of the black soybean hull extract in preparation of a medicine for treating Alzheimer's disease. The preparation method of the black soybean hull extract does not need toxic organic solvent extraction, is different from only extraction of black soybean hull anthocyanin, can reserve active ingredients of black soybean seed coats to the maximum extent, improves the yield and extraction efficiency of a final compound product, and reduces toxic substances possibly generated in the preparation process. Wild C57BL / 6 mice and disease model APP / Ps1 mice are utilized to research the influence of the black soybean hull extract on the Alzheimer's disease. Compared with disease model mice fed with standard mixed grain feed, the black soybean hull extract is added into diet, so that the learning and memory ability and the movement ability of the disease model mice can be remarkably improved, and the anxiety degree of the disease model mice is reduced. Therefore, the black bean peel extract has a remarkable treatment effect on the Alzheimer's disease. The black bean peel extract has the following advantages in the aspect of treating the Alzheimer's disease: the natural plant extract is non-toxic and has no side effect; raw materials are easily available and the preparation cost is low; the diet intake is convenient and practical. The black soybean hull extract has important scientific significance and application value for treating the Alzheimer's disease.

The invention relates to the technical field of animal model construction, in particular to a construction method and application of an ICI-related myocarditis mouse model closer to clinical application. The ICI-related myocarditis mouse model closer to clinical application is successfully constructed by constructing a liver metastatic tumor model of a C57BL / 6 mouse and then injecting ICIs. The construction method provided by the invention has the advantages of simplicity in operation, low cost and high modeling rate (50-60%), and the ICI-related myocarditis mouse model constructed by the method is closer to clinical application. Meanwhile, the ICI-related myocarditis mouse model obtained by the construction method provided by the invention can also be used for ICI-related myocarditis model mechanism research, ICI-related myocarditis drug screening or ICI-related myocarditis treatment method development and the like.

The invention provides a lung cancer cell LLC-ML2 as well as an establishment method and application thereof. The lung cancer cells are used for highly expressing CD18 molecules, Strc molecules, Cd79a molecules, Amigo2 molecules, Plet1 molecules, Angptl4 molecules and Plac1 molecules; ddx3y, Cbr3, Sox11, Pid1, Kdm5d, Eif2s3y and Capn6 molecules are not expressed or are subjected to low expression. The LLC cell strain is obtained by inoculating common LLC cells to a C57BL / 6 mouse, taking a lung metastatic focus for culture, inoculating primarily cultured metastatic focus cells to the C57BL / 6 again, taking the lung metastatic focus for different clone culture, and screening. Through two times of lung metastatic focus tumorigenesis and screening, compared with LLC cells, the lung cancer cells are shorter in use time for constructing a metastasis model, and the metastasis rate of main organs is higher; an efficient cell model is provided for better researching a tumor invasion and metastasis mechanism.

The invention belongs to the technical field of medicines, and particularly relates to application of CARNS1 in Parkinson's disease (PD). The research finds that CARNS1 is highly expressed in striatum and nigra brain regions in C57BL / 6 mouse brains, is positioned in dopaminergic neurons in the nigra brain regions, and is down-regulated in MPTP and alpha-syn animal models and MPP + cell models; the nigra region CARNS1 knocks down and aggravates MPTP-induced dyskinesia and neurodegeneration, and the exogenous supplement carnosine can partially reverse phenotypes; the overexpression of the wild type CARNS1 can be used for relieving the neurodegeneration in MPTP and alpha-syn models. The invention clarifies the regulation role of CARNS1 in PD, provides a new perspective for understanding the pathogenesis of PD, and prompts that the CARNS1-carnosine metabolic axis may become an important target for intervening the pathological process of PD.

The invention belongs to the technical field of tumor treatment, and particularly relates to a CRISPR library screening method of genes related to ovarian cancer cell growth, tumor formation and immune escape. The sgRNA library comprises sgRNA which is selected from 80 genes in a MusCK library in a targeting manner. According to the invention, a targeted MusCK library of 922 genes related to the starting, progression and immunoregulation of tumors is used, and a P53- / -Carm1OE Ccne1OE KrasOE mouse ovarian cancer cell line, a C57BL / 6 mouse and a BALB / c-nu mouse are respectively adopted for high-throughput screening, so that the immunoregulation of tumors is realized. A series of confirmed and unverified key genes for high-grade serous ovarian cancer cell growth, tumor formation and immune escape function exertion are successfully screened, and an important theoretical and experimental foundation is laid for finding a novel treatment target of the high-grade serous ovarian cancer; and breakthrough in targeted therapy of high-grade serous ovarian cancer is facilitated.

The invention belongs to the technical field of animal model establishment, and discloses an establishment method and application of a chronic oral ferric citrate induced Parkinson mouse model, C57BL / 6 mice are fed with mouse maintenance food (high-iron feed) added with 2.25% ferric citrate for 22 weeks, and then a 5% ferric citrate solution is used for intragastric administration for 4 weeks. Finally, behavioral evaluation is carried out through behavioral tests such as an open field test, a rotating rod test, a pole climbing test, a holding power test and a Y labyrinth test, and the tests such as the rotating rod test, the pole climbing test and the holding power test show that the PD model mouse has remarkable motor function impairment such as reduction of motor coordination, muscular tension and balance force; open field tests and Y maze show that learning and memory functions of mice are impaired, and cognitive impairments such as anxiety mood occur. Clinical chronic disease conditions of Parkinson's disease are simulated, and the chronic model is more suitable for monitoring early changes and screening early diagnosis indexes of Parkinson's disease; the method has the characteristics that the behavioral disorder can be quantified, and DA energy neuron degeneration loss characteristic lesion is realized.

The invention belongs to the technical field of medical experimental animal models, and particularly relates to a stable and high-reproducibility severe acute pancreatitis mouse model construction method, a quantitative evaluation system and application thereof, and the method comprises the following steps: selecting a male C57BL / 6 mouse of 6-8 weeks old, adaptively feeding for one week, and then carrying out model induction; the preparation method comprises the following steps: carrying out intraperitoneal injection on leptofrog at the dosage of 100 mu g / kg once every 1 hour, and continuously injecting for 7 times; within 2 hours after completion of the seventh time of rain frog element injection, lipopolysaccharide is injected into the abdominal cavity, and the dosage is 12 mg / kg; pathological and physiological index evaluation is carried out on the mouse 24 hours after the first time of rain frog element injection, and multi-batch verification experiments prove that the inter-batch fluctuation range of the model constructed by the invention on the death rate, the pathological score, the weight change and other key indexes is controlled within + / -5%, so that the repeatability and comparability of experimental results are ensured.

The invention relates to the technical field of lung adenocarcinoma cell lines, in particular to a mouse Trp53 / Keap1 mutant lung adenocarcinoma cell line (Mus musculus) as well as construction and application of the mouse Trp53 / Keap1 mutant lung adenocarcinoma cell line. The mouse Trp53 / Keap1 mutant lung adenocarcinoma cell line (Mus musculus) constructed by the invention is delivered to the China Center for Type Culture Collection on May 18, 2025, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: C2025163. The cell line is derived from a lung adenocarcinoma model of a C57BL / 6 strain mouse, carries the most common Keap1 mutation in lung adenocarcinoma, is the first known lung adenocarcinoma mouse cell line only carrying Keap1 and Trp53 mutations in the world at present, has the in-vivo tumorigenesis ability of the C57BL / 6 mouse, and fills the blank of the mouse mutant cell line in the level.

The application provides a construction method and application of a preeclampsia animal model, and belongs to the technical field of construction of animal models. The construction method of the preeclampsia animal model provided by the application comprises the following steps: during pregnancy of a female mouse, phthalic acid or an adenovirus is given to inhibit activity of QPRT, and thus the preeclampsia animal model is obtained. The female mouse is a 8-week-old female C57BL / 6 mouse, the female mouse is given the phthalic acid or the adenovirus at the 10.5th day or the 16.5th day of pregnancy, the dosage of the phthalic acid is 50 mg / kg, the dosage of the adenovirus is 10 9 copies / ml. The construction method of the animal model provided by the application has the advantages of simple operation, the drug can be concentrated in the local maternal-fetal interface to play a role by the drug administration mode of uterine cavity perfusion, and the construction method can eliminate the whole-body symptoms caused by intraperitoneal injection and intravenous injection; and the mouse model can better simulate the clinical symptoms and indexes of patients with preeclampsia, and provides a new mouse model for research on the pathogenesis of preeclampsia.

The twitcher mouse model is a main animal model for researching the pathogenesis and treatment method of GLD disease at present, and the model is caused by a spontaneous mutation of a C57BL / 6 mouse model GALC At present, a commonly used genotype identification method is time-consuming and expensive. In order to overcome the defect, the special identification primer is designed, the PCR method is adopted, and the restriction endonuclease Eco RV is used for single enzyme digestion verification, so that a rapid, efficient and economic genotype identification method is established, and a reference for the genotype identification of the twitcher mouse is provided.

The application discloses a macrocyclic naphthalene sulfonamide derivative or a pharmaceutical salt thereof, and a structure general formula is as follows: The macrocyclic naphthalene sulfonamide derivative or the pharmaceutical salt thereof has a protective effect on an LPS-induced BV2 cell inflammation model as a Keap1-Nrf2 protein interaction inhibitor, and has a preventive and therapeutic effect on CUMS modeling C57BL / 6 mouse depression.

The invention belongs to the technical field of pharmacy, and discloses application of isoimperatorin in preparation of a medicine for treating fungal keratitis. The invention proposes that the isoimperatorin has a treatment effect on fungal keratitis for the first time. C57BL / 6 mice are adopted to establish a fungal keratitis model, the influence of isoimperatorin on model mouse cornea clinical score, neutrophil recruitment and interleukin 1 beta expression is researched, the influence of isoimperatorin on a TLR4 / MyD88 / IKK / NF-kappa B signal channel is verified, and meanwhile the influence of isoimperatorin on cell apoptosis and macrophage polarization is verified.

The invention belongs to the technical field of construction of cell models, and particularly relates to a method for constructing a hyperuricemia testicular interstitial cell model. Comprising the following steps: (1) selecting an 8-week-old male C57BL / 6 mouse, dissecting, collecting testis, removing testis albuginea, cutting into fragments, digesting by utilizing collagenase IV, filtering, centrifuging, discarding supernatant, diluting cell suspension, adding luteinizing hormone receptor coupled fluorescein to mark testis interstitial cells, and sorting by utilizing flow cytometry to obtain testis interstitial cell suspension; (2) counting by using a blood cell counting plate, diluting the testicular interstitial cells, inoculating the testicular interstitial cells into a 24-pore plate, and culturing the testicular interstitial cells in a cell culture box; and (3) after 24-48 hours, taking out the 24-well plate, discarding cell supernate, cleaning with PBS, adding a uric acid solution, and continuously culturing to obtain the hyperuricemia testicular interstitial cell model. The obtained interstitial cell model can be used for exploring various function change mechanisms of the testicular interstitial cells in a hyperuricemia environment, and is simple to operate, effective, high in repeatability and short in time consumption.

The application provides lung cancer cells and a method for establishing the same and application. The lung cancer cells highly express CD18, Strc, Cd79a, Amigo2, Plet1, Angptl4 and Plac1 molecules; do not express or lowly express Ddx3y, Cbr3, Sox11, Pid1, Kdm5d, Eif2s3y and Capn6 molecules. The lung cancer cells are obtained by inoculating common LLC cells into C57BL / 6 mice, culturing lung metastatic foci, inoculating the primary cultured metastatic foci cells into C57BL / 6 again, culturing different clones of lung metastatic foci again, and screening. After twice lung metastatic foci tumorigenesis and screening, compared with LLC cells, the lung cancer cells are shorter in use time for constructing a metastasis model, and higher in metastasis rate of main organs; and the lung cancer cells provide a high-efficiency cell model for better studying the mechanism of tumor invasion and metastasis.

The invention discloses a traditional Chinese medicine cold-heat property evaluation method based on small animal metabolism analysis and body temperature monitoring, and belongs to the technical field of traditional Chinese medicine modernization evaluation. A C57BL / 6 mouse is used as a model, a small animal energy metabolism monitoring system is used for continuously collecting metabolic indexes of the mouse, and the metabolic indexes are compared with a blank control group according to the metabolic indexes, so that the cold-heat property of the traditional Chinese medicine is objectively judged. The influence of the processing technology on the medicine property is further evaluated by comparing the metabolic indexes of the same crude traditional Chinese medicine product and the processed product. In order to improve the discrimination reliability, multi-modal data fusion discrimination can be carried out in combination with a body temperature change index measured on a cold / heat syndrome model animal. The invention provides a rapid, quantitative and repeatable traditional Chinese medicine property evaluation scheme.

This invention discloses the application of a traditional Chinese medicine composition in the preparation of a drug for treating sarcopenia, wherein the traditional Chinese medicine composition consists of Astragalus membranaceus and Anemarrhena asphodeloides. The study found that the combination of Astragalus membranaceus and Anemarrhena asphodeloides can significantly improve the differentiation function of C2C12 myoblasts induced by high glucose and inhibit lipid deposition, and improve skeletal muscle mass, muscle strength, and motor function in a streptozotocin-induced C57BL / 6 diabetic sarcopenia mouse model. In vitro and in vivo experiments have confirmed that this drug has significant effects in improving muscle atrophy, enhancing motor function, and restoring muscle strength; it can effectively increase the cross-sectional area of ​​muscle fibers, promote myotube fusion, and accelerate damage repair, showing a clear potential to inhibit diabetic muscle atrophy. This provides an effective traditional Chinese medicine compound intervention strategy for the clinical treatment of diabetic sarcopenia and has good prospects for development and application.

Use of apolipoprotein H (APOH) in the manufacture of medicaments for prevention and / or treatment of fatty liver disease and related diseases is provided. Using wild type C57BL / 6 mice as controls, the serum transaminase level in peripheral blood of 10-week-old ApoH gene knockout mice (C57BL / 6 ApoH− / −) was assessed. The results showed that the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are significantly increased. The triglyceride (TG) level was further assessed in the liver and the results showed that the TG level was significantly increased in the liver of ApoH− / − mice. Based on the findings that low APOH expression induces steatohepatitis, promotes the progression of chronic liver diseases (CLDs), and is related to the prognosis of end-stage liver diseases, it is conducive to the development of precise targeted therapeutic drugs for treating fatty liver disease and improving the prognosis of the end-stage liver diseases.

The invention belongs to the technical field of pharmacy, and discloses application of sennoside A in preparation of a medicine for treating fungal keratitis. The invention proposes that sennoside A has a treatment effect on fungal keratitis for the first time. A fungal keratitis model is established by adopting a C57BL / 6 mouse, the influence of sennoside A on corneal clinical score, neutrophil recruitment, macrophage recruitment and interleukin 1 beta expression of the model mouse is researched, the influence of sennoside A on a Caspase-1 / GSDMD signal channel is verified, and meanwhile, the influence of sennoside A on neutrophil activity and macrophage polarization is verified.